QOL Medical to purchase Evoke Pharma for $11.00 per share in cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Acquisition Details: QOL Medical will acquire Evoke Pharma for $11.00 per share in cash, a deal unanimously approved by both companies' Boards of Directors, expected to close by the end of 2025.
Strategic Value: The acquisition highlights the strategic importance of Evoke's product, GIMOTI, the first FDA-approved nasal spray for treating diabetic gastroparesis in adults.
Tender Offer Conditions: QOL Medical will initiate a tender offer for all outstanding shares of Evoke, contingent on the tender of a majority of shares and other customary closing conditions.
Financing and Timeline: The transaction will be financed with cash on hand and is anticipated to close in the fourth quarter of 2025, without any financing condition.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
